Phio Pharmaceuticals Announces Participation in Live Virtual Non-Deal Roadshow Series

Live Presentation and Q&A: Thursday, May 28, 2026 12 PM EDT

King of Prussia, Pennsylvania--(Newsfile Corp. - May 26, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL^® gene silencing technology to eliminate cancer. Phio Pharmaceuticals announced today that Robert Bitterman, CEO and Chairman of the Board, will present an overview of the Company's INTASYL^® siRNA platform, including its lead clinical candidate PH-762 for the treatment of cutaneous carcinomas. The presentation will be followed by a live Q&A session.

"We look forward to participating in the Renmark Virtual Non-Deal Roadshow, where we will discuss why we believe INTASYL represents a differentiated and promising approach in immuno-oncology," said Robert Bitterman, CEO and Chairman of Phio Pharmaceuticals.

Phio's presentation and live Q&A will take place on Thursday May 28, 2026, at 12 PM EDT in the live Virtual Non-Deal Roadshow Series hosted by Renmark Financial Communications Inc.

REGISTER HERE: Renmark Virtual Non-Deal Roadshow NASDAQ - PHIO | Event Registration | Renmark Financial Communications

Please Note: If the link does not work, please copy and paste into your browser. To ensure smooth connectivity, please access the link above using the latest version of Google Chrome.

A replay of the event may be accessed on the Renmark Financial Communications Inc. website at https://www.renmarkfinancial.com/vndrs.

You May Also Be Interested In

• FDA clears first over-the-counter glucose monitor for children
• Circle board member resigns after nearly 13 years of service
• Venu Holding enters $250 million at-the-market stock offering agreement